BIOCON
₹309.00
+3.15 (1.03%)
  • Advice
  • Hold
18 May, 2024 09:27 BSE: 532523 NSE: BIOCONISIN: INE376G01013

Start SIP in Biocon

Start SIP

Biocon Performance

Day Range

  • Low 307
  • High 310
₹ 309

52 Week Range

  • Low 218
  • High 321
₹ 309
  • Open Price308
  • Previous Close306
  • Volume157311

Biocon Share Price

  • Over 1 Month +16.87%
  • Over 3 Month +7.46%
  • Over 6 Month +32.44%
  • Over 1 Year +25.59%

Biocon Key Statistics

P/E Ratio 36.3
PEG Ratio 0.3
Market Cap Cr 37,099
Price to Book Ratio 1.5
EPS -0.1
Dividend 0.5
Relative Strength Index 58.25
Money Flow Index 53.17
MACD Signal 8.82
Average True Range 11.68
Biocon Financials
IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 533563519513507
Operating Expenses Qtr Cr 480492452441551
Operating Profit Qtr Cr 52716772-44
Depreciation Qtr Cr 3031313029
Interest Qtr Cr 4056554848
Tax Qtr Cr 89113-15
Net Profit Qtr Cr 142435471,811
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 2,3202,264
Operating Expenses Annual Cr 1,8651,969
Operating Profit Annual in Cr 26324
Depreciation Cr 121117
Interest Annual Cr 19970
Tax Annual Cr 31123
Net Profit Annual Cr 1192,848
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr -123219
Cash from Investing Activity Annual Cr -296-1,178
Cash from Financing Annual Activity Cr 3441,039
Net Cash Flow Annual Cr 81
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 10,91210,916
Fixed Assets Annual Cr 1,5181,305
Total Non Current Assets Annual Cr 11,00810,464
Total Current Assets Annual Cr 2,7602,566
Total Assets Annual Cr 13,76813,030
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 9191
ROE Annual % 126
ROCE Annual % 31
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2115
IndicatorMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 3,8643,5493,4623,4233,774
Operating Expenses Qtr Cr 3,0013,0272,7212,7082,777
Operating Profit Qtr Cr 916927742714997
Depreciation Qtr Cr 407415389358364
Interest Qtr Cr 227267248233249
Tax Qtr Cr 9655423582
Net Profit Qtr Cr 136660126101313
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 15,62111,550
Operating Expenses Annual Cr 11,4578,663
Operating Profit Annual in Cr 3,2992,512
Depreciation Cr 1,5691,113
Interest Annual Cr 974419
Tax Annual Cr 227254
Net Profit Annual Cr 1,023463
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 2,9541,853
Cash from Investing Activity Annual Cr -1,005-14,282
Cash from Financing Annual Activity Cr -2,33313,049
Net Cash Flow Annual Cr 619
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 19,78417,867
Fixed Assets Annual Cr 22,26520,649
Total Non Current Assets Annual Cr 40,89239,709
Total Current Assets Annual Cr 15,17912,334
Total Assets Annual Cr 56,07152,043
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 211187
ROE Annual % 53
ROCE Annual % 64
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2826

Biocon Technicals

EMA & SMA

Current Price
₹309.00
+3.15 (1.03%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹297.85
  • 50 Day
  • ₹285.47
  • 100 Day
  • ₹275.93
  • 200 Day
  • ₹268.00
  • 20 Day
  • ₹298.14
  • 50 Day
  • ₹278.92
  • 100 Day
  • ₹275.73
  • 200 Day
  • ₹262.87

Biocon Resistance and Support

PIVOT
₹306.92
Resistance
First Resistance 310.18
Second Resistance 314.52
Third Resistance 317.78
RSI 58.25
MFI 53.17
MACD Single Line 8.82
MACD 8.63
Support
First Support 302.58
Second Support 299.32
Third Supoort 294.98

Biocon Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 13,158,794 492,402,071 37.42
Week 10,791,449 374,139,537 34.67
1 Month 12,789,268 502,234,564 39.27
6 Month 7,578,016 310,925,979 41.03

Biocon Result Highlights

Biocon Synopsis

NSE-Medical-Biomed/Biotech

Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1992.90 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2023. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.
Market Cap 36,720
Sales 2,127
Shares in Float 46.82
No of funds 253
Yield 0.49
Book Value 3.37
U/D Vol ratio 1.3
LTDebt / Equity 12
Alpha -0.08
Beta 1.54

Biocon Shareholding Pattern

Owner NameMar-24Dec-23Sep-23Jun-23
Promoters 60.64%60.64%60.64%60.64%
Mutual Funds 8.57%9.31%8.26%7.47%
Insurance Companies 5.01%5.12%5.76%5.09%
Foreign Portfolio Investors 5.63%6.55%7.97%9.52%
Financial Institutions/ Banks 0.01%
Individual Investors 15.53%14.47%13.61%13.34%
Others 4.61%3.91%3.76%3.94%

Biocon Management

Name Designation
Ms. Kiran Mazumdar Shaw Executive Chairperson
Mr. Siddharth Mittal Managing Director & CEO
Prof. Ravi Rasendra Mazumdar Non Exe.Non Ind.Director
Mr. Eric Vivek Mazumdar Non Exe.Non Ind.Director
Mr. Meleveetil Damodaran Lead Independent Director
Dr. Vijay Kumar Kuchroo Independent Director
Mr. Bobby Kanubhai Parikh Independent Director
Mr. Peter John Bains Independent Director
Mr. Naina Lal Kidwai Independent Director

Biocon Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Biocon Corporate Action

Date Purpose Remarks
2024-05-16 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-10 Quarterly Results
2023-08-10 Quarterly Results
2023-05-23 Audited Results & Final Dividend
Date Purpose Remarks
2023-07-07 FINAL Rs.1.50 per share(30%)Final Dividend
2022-07-01 FINAL Rs.0.50 per share(10%)Final Dividend

About Biocon

Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bangalore, India. The company has more than 13,500  employees. It focuses on all phases of the product cycle from researching to development and then introducing them to the market.  They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies. 

Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine), etc. 

Biocon FAQs

What is Share Price of Biocon ?

Biocon share price is ₹309 As on 18 May, 2024 | 09:13

What is the Market Cap of Biocon ?

The Market Cap of Biocon is ₹37098.5 Cr As on 18 May, 2024 | 09:13

What is the P/E ratio of Biocon ?

The P/E ratio of Biocon is 36.3 As on 18 May, 2024 | 09:13

What is the PB ratio of Biocon ?

The PB ratio of Biocon is 1.5 As on 18 May, 2024 | 09:13

Is it a good time to invest in Biocon Limited?

Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.

How many times has Biocon Limited given dividends since 2004?

Biocon Ltd. has declared 17 dividends since July 1, 2004.

What is the stock price CAGR of Biocon Limited?

The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.

What is the debt-to-equity ratio of Biocon Limited?

The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.

What is the ROE of the Biocon Limited?

The ROE of Biocon Limited is 9% which is fair but needs improvement.

Who is the Managing Director of Biocon Limited?

Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.

Is Biocon a good stock to buy?

According to the record analysis of moneyworks4me, Biocom limited is an average quality company. 

How to buy shares of Biocon Ltd?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q2FY23